Real-world CML management in line with ELN guidelines

By Shreeya Nanda, Senior medwireNews Reporter

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia (CML) is in accordance with the European LeukaemiaNet (ELN) recommendations, finds a real-world clinical practice study.

Of 697 patients attending consultations in clinical practice or a clinical trial over a 30-day period in 2013, 62.8% were receiving first-line treatment at the time of inclusion. The median duration since CML diagnosis was 4 years.

The majority (72.4%) of patients had been treated with the first-generation tyrosine kinase inhibitor (TKI) imatinib while 23.3% received the second-generation TKIs dasatinib or nilotinib.

Among 307 patients on first-line therapy in clinical practice, data on molecular response at 3, 6, 12 or 18 months was available for 87%, the research team reports in the British Journal of Haematology.

Cytogenetic response was assessed most often at 6 months, at 60.1% compared with 49.0% at 12 months and 34.1% at 18 months. By contrast, a higher proportion of patients underwent molecular monitoring at 12 months than at other timepoints, at 80.1% versus 74.0% at 6 months and 75.5% at 18 months.

The researchers highlight the effect of ELN recommendations on practice - for instance, cytogenetic response at 3 months was evaluated in 18.4% before 2009, rising to 43.7% subsequently, coinciding with the recommendation appearing in the 2009 update to the ELN guidelines. The evaluation of molecular response also increased after 2009, with, for instance, 27.6% of patients assessed at the 3-month timepoint before 2009 versus 81.6% after 2009.

Moreover, 35.8% of patients in clinical practice had not achieved major molecular response (BCR-ABL1 transcript level ≤0.1%) at 12 months; according to the 2013 update, these patients would fall into the warning category, say the study authors. Just 5.1% had BCR-ABL1 levels above 1% at this timepoint, corresponding to the definition of treatment failure. If treated today, this subset of patients would be recommended for a treatment switch, if alternatives were available, they add.

Gabriel Etienne, from Institut Bergonié in Bordeaux, France, and co-investigators summarise: "[T]his study, performed in an unselected everyday practice population of [chronic phase-CML] patients, suggests that monitoring of cytogenetic and molecular responses usually required in clinical trials and in line with ELN recommendations, seems to have been transferred to patients treated in real-life practice.

"The majority of patients still receiving first-line treatment are in optimal response, with few being classified as being in the warning area or [failing treatment]."


Br J Haematol 2016; Advance online publication

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Pioneering trial offers hope for patients with Parkinson’s disease